Skip to content

Study · Not a test of the peptide alone · 2018

6 results

Calmodulin-like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease.

Kusakari S, Nawa M, Sudo K, Matsuoka M

Journal of neurochemistry18 Dec 2017Cited by 14 (Europe PMC)

PMID29164613 (opens in a new tab)DOI10.1111/jnc.14258 (opens in a new tab)PepBankPUB-29164613
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 01AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PSEN1dE9 Alzheimer mice, over-expression of the mouse CLSP-1 gene attenuated spatial learning impairment.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity reduced spatial learning problems.

    Peptide
    Humanin
    Outcome
    DecreaseSpatial learning impairment
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    We found that over-expression of the mouse CLSP-1 gene attenuated spatial learning impairment, the loss of a presynaptic marker synaptophysin, and the inactivation of STAT3 in the APPswe/PSEN1dE9 mice.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 02AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In APPswe/PSEN1dE9 mice, CLSP-1 over-expression attenuated the loss of synaptophysin.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity reduced the loss of a synapse marker.

    Peptide
    Humanin
    Outcome
    DecreaseLoss of presynaptic marker synaptophysin
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    We found that over-expression of the mouse CLSP-1 gene attenuated spatial learning impairment, the loss of a presynaptic marker synaptophysin, and the inactivation of STAT3 in the APPswe/PSEN1dE9 mice.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In APPswe/PSEN1dE9 mice, CLSP-1 over-expression attenuated the inactivation of STAT3.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity reduced the switching off of STAT3.

    Peptide
    Humanin
    Outcome
    DecreaseSTAT3 inactivation
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    We found that over-expression of the mouse CLSP-1 gene attenuated spatial learning impairment, the loss of a presynaptic marker synaptophysin, and the inactivation of STAT3 in the APPswe/PSEN1dE9 mice.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  4. 04AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In APPswe/PSEN1dE9 mice, CLSP-1 over-expression did not change Abeta levels.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity did not change amyloid-beta levels.

    Peptide
    Humanin
    Outcome
    No significant changeAbeta levels
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    On the other hand, CLSP over-expression did not affect levels of Aβ, soluble Aβ oligomers, or gliosis.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  5. 05AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In APPswe/PSEN1dE9 mice, CLSP-1 over-expression did not change soluble Abeta oligomer levels.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity did not change soluble amyloid-beta oligomers.

    Peptide
    Humanin
    Outcome
    No significant changeSoluble Abeta oligomers
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    On the other hand, CLSP over-expression did not affect levels of Aβ, soluble Aβ oligomers, or gliosis.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  6. 06AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In APPswe/PSEN1dE9 mice, CLSP-1 over-expression did not change gliosis.

    In plain wordsIn mice with Alzheimer-like disease, extra CLSP gene activity did not change gliosis.

    Peptide
    Humanin
    Outcome
    No significant changeGliosis
    Study

    mousen: not reported in source

    APPswe/PSEN1dE9 mice with CLSP-1 over-expression
    Outcome group
    Inflammation markers · Nervous system and cognition

    Source sentences

    Summary
    To investigate the role of CLSP in the AD pathogenesis in vivo, we generated mouse CLSP-1 transgenic mice, crossed them with the APPswe/PSEN1dE9 mice, a model mouse of AD, and examined the effect of CLSP over-expression on the pathological phenotype of the AD mouse model.
    1 context sentence
    Summary · context
    On the other hand, CLSP over-expression did not affect levels of Aβ, soluble Aβ oligomers, or gliosis.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.